Get the Stockscreener App
50.27
0.52%
0.26
After Hours:
50.27
Haemonetics Corp stock is traded at $50.27, with a volume of 453.03K.
It is up +0.52% in the last 24 hours and down -0.44% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$50.01
Open:
$49.9
24h Volume:
453.03K
Relative Volume:
0.47
Market Cap:
$2.42B
Revenue:
$1.35B
Net Income/Loss:
$163.34M
P/E Ratio:
15.34
EPS:
3.2763
Net Cash Flow:
$189.17M
1W Performance:
-1.84%
1M Performance:
-0.44%
6M Performance:
-21.27%
1Y Performance:
-29.67%
1-Day Range:
$49.23
$50.33
1-Week Range:
$48.98
$51.00
52-Week Range:
$47.31
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
50.27 | 2.41B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
123.84 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.59 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
358.16 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
90.20 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.07 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Is Haemonetics Corporation stock dividend growth reliableRate Cut & Weekly Market Pulse Updates - newser.com
When is the best time to exit Haemonetics CorporationRate Hike & Precise Swing Trade Entry Alerts - newser.com
Published on: 2025-11-02 20:37:56 - newser.com
Can Haemonetics Corporation (HAZ) stock test all time highsJuly 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
How Haemonetics Corporation stock benefits from digital adoptionJuly 2025 Final Week & Low Drawdown Trading Strategies - newser.com
Haemonetics (HAE) to Release Earnings on Thursday - MarketBeat
Using RSI to spot recovery in Haemonetics Corporation2025 Earnings Impact & Daily Market Momentum Tracking - newser.com
Is Haemonetics Corporation (HAZ) stock prepared for digital transitionMarket Sentiment Summary & AI Forecast for Swing Trade Picks - newser.com
Will Haemonetics Corporation (HAZ) stock issue positive guidanceMarket Trend Report & Free Technical Confirmation Trade Alerts - newser.com
Is Haemonetics Corporation stock a defensive play in 2025Earnings Growth Report & Precise Swing Trade Entry Alerts - newser.com
Haemonetics Corporation (HAE) Stock forecasts - Yahoo! Finance UK
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
How Recent Developments Are Shaping the Haemonetics Investment Story - Yahoo Finance
Using data filters to optimize entry into Haemonetics CorporationQuarterly Performance Summary & Weekly Watchlist for Consistent Profits - newser.com
Can Haemonetics Corporation stock weather global recessionEarnings Risk Summary & Detailed Earnings Play Alerts - newser.com
Using AI based signals to follow Haemonetics CorporationTrade Exit Report & Safe Entry Zone Identification - newser.com
Can Haemonetics Corporation stock outperform in 2025 bull marketEarnings Performance Report & Capital Efficiency Focused Strategies - fcp.pa.gov.br
Will Haemonetics Corporation stock outperform value stocks2025 Volume Leaders & Accurate Technical Buy Alerts - newser.com
What the charts say about Haemonetics Corporation todayWeekly Trend Recap & Technical Confirmation Alerts - newser.com
Will Haemonetics Corporation (HAZ) stock sustain bullish trend into 2025Market Performance Recap & Consistent Profit Alerts - newser.com
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Dynamics - Markets Mojo
Riverwater Partners LLC Sells 5,091 Shares of Haemonetics Corporation $HAE - MarketBeat
Does Haemonetics Corporation fit your quant trading modelJuly 2025 Earnings & Consistent Growth Equity Picks - newser.com
Haemonetics (NYSE:HAE) Cut to Sell (D+) at Weiss Ratings - MarketBeat
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):